BioNTech (BNTX) to Release Quarterly Earnings on Monday

BioNTech (NASDAQ:BNTX) will be issuing its quarterly earnings data before the market opens on Monday, August 5th. Analysts expect the company to announce earnings of ($1.92) per share for the quarter. BioNTech has set its FY 2024 guidance at EPS.Parties interested in participating in the company’s conference call can do so using this link.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, May 6th. The company reported ($1.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). BioNTech had a net margin of 4.01% and a return on equity of 0.55%. The company had revenue of $203.69 million during the quarter, compared to the consensus estimate of $589.96 million. On average, analysts expect BioNTech to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioNTech Price Performance

Shares of BioNTech stock opened at $82.01 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.38 and a quick ratio of 11.16. BioNTech has a fifty-two week low of $78.02 and a fifty-two week high of $125.83. The firm has a fifty day moving average price of $88.11 and a two-hundred day moving average price of $90.81. The company has a market cap of $19.50 billion, a PE ratio of 164.02 and a beta of 0.23.

Analyst Upgrades and Downgrades

BNTX has been the subject of a number of analyst reports. TD Cowen raised their price objective on shares of BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a report on Tuesday, May 7th. HC Wainwright reiterated a “buy” rating and set a $113.00 target price on shares of BioNTech in a research report on Thursday. BMO Capital Markets dropped their target price on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research report on Tuesday, May 7th. HSBC upgraded shares of BioNTech from a “hold” rating to a “buy” rating in a research report on Friday. Finally, Evercore ISI initiated coverage on shares of BioNTech in a research report on Tuesday, May 14th. They set an “inline” rating and a $100.00 target price for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $111.70.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.